Trial: 202201030

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors

Phase

I/II (Cancer Control)

Principal Investigator

Davis, Andrew

Disease Site

Breast; Colon; Esophagus; Lung; Pancreas; Rectum; Stomach

Learn more about this study at: clinicaltrials.gov